BIOMAT Database Logo BIOMAT Database Logo

Endogenous platelet-activating factor and anti-platelet-activating factor in patients with renovascular hypertension. 1988

F Masugi, and T Ogihara, and S Saeki, and K Sakaguchi, and Y Kumahara, and K Satouchi, and M Oda, and K Saito, and K Tokunaga
Department of Medicine and Geriatrics, Osaka University Medical School, Japan.

Renovascular hypertension is relieved by percutaneous transluminal renal angioplasty. In four patients with renovascular hypertension, platelet-activating factor (PAF) was found to be released into the ipsilateral renal venous blood after percutaneous transluminal renal angioplasty, but was not found in the contralateral renal venous blood following this procedure. Anti-platelet-activating factor with a lipid-like property was also found, and its polarity was slightly lower than that of PAF judging by its behavior on thin layer chromatography. Anti-platelet-activating factor completely blocked the aggregation of rabbit platelets induced by PAF, ADP or arachidonic acid. These results indicate that PAF and anti-platelet-activating factor are released into renal venous blood following percutaneous transluminal renal angioplasty in patients with renovascular hypertension.

UI MeSH Term Description Entries
D006978 Hypertension, Renovascular Hypertension due to RENAL ARTERY OBSTRUCTION or compression. Hypertension, Goldblatt,Goldblatt Syndrome,Goldblatt Hypertension,Renovascular Hypertension,Syndrome, Goldblatt
D008297 Male Males
D010972 Platelet Activating Factor A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION. AGEPC,Acetyl Glyceryl Ether Phosphorylcholine,PAF-Acether,Phosphorylcholine, Acetyl Glyceryl Ether,1-Alkyl-2-acetyl-sn-glycerophosphocholine,Platelet Aggregating Factor,Platelet Aggregation Enhancing Factor,Platelet-Activating Substance,Thrombocyte Aggregating Activity,1 Alkyl 2 acetyl sn glycerophosphocholine,Aggregating Factor, Platelet,Factor, Platelet Activating,PAF Acether,Platelet Activating Substance
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D012082 Renal Veins Short thick veins which return blood from the kidneys to the vena cava. Renal Vein,Vein, Renal,Veins, Renal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000244 Adenosine Diphosphate Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position. ADP,Adenosine Pyrophosphate,Magnesium ADP,MgADP,Adenosine 5'-Pyrophosphate,5'-Pyrophosphate, Adenosine,ADP, Magnesium,Adenosine 5' Pyrophosphate,Diphosphate, Adenosine,Pyrophosphate, Adenosine
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

F Masugi, and T Ogihara, and S Saeki, and K Sakaguchi, and Y Kumahara, and K Satouchi, and M Oda, and K Saito, and K Tokunaga
Role of endogenous platelet-activating factor (PAF) in endotoxin-induced portal hypertension in rats.
January 1992, Journal of gastroenterology and hepatology,
F Masugi, and T Ogihara, and S Saeki, and K Sakaguchi, and Y Kumahara, and K Satouchi, and M Oda, and K Saito, and K Tokunaga
Regulation of platelet-activating factor receptor gene expression in vivo by endotoxin, platelet-activating factor and endogenous tumour necrosis factor.
March 1997, The Biochemical journal,
F Masugi, and T Ogihara, and S Saeki, and K Sakaguchi, and Y Kumahara, and K Satouchi, and M Oda, and K Saito, and K Tokunaga
Platelet-activating factor and bacteremia-induced pulmonary hypertension.
February 2000, The Journal of surgical research,
F Masugi, and T Ogihara, and S Saeki, and K Sakaguchi, and Y Kumahara, and K Satouchi, and M Oda, and K Saito, and K Tokunaga
Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease.
November 2002, Circulation,
F Masugi, and T Ogihara, and S Saeki, and K Sakaguchi, and Y Kumahara, and K Satouchi, and M Oda, and K Saito, and K Tokunaga
Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies.
December 2017, Auto- immunity highlights,
F Masugi, and T Ogihara, and S Saeki, and K Sakaguchi, and Y Kumahara, and K Satouchi, and M Oda, and K Saito, and K Tokunaga
Platelet activating factor and one-kidney, one clip hypertension.
June 1990, Hypertension (Dallas, Tex. : 1979),
F Masugi, and T Ogihara, and S Saeki, and K Sakaguchi, and Y Kumahara, and K Satouchi, and M Oda, and K Saito, and K Tokunaga
Platelet-activating factor and platelet-activating factor antagonists in acute pancreatitis.
January 1999, Digestive surgery,
F Masugi, and T Ogihara, and S Saeki, and K Sakaguchi, and Y Kumahara, and K Satouchi, and M Oda, and K Saito, and K Tokunaga
Platelet activating factor-induced shock and intestinal necrosis in the rat: role of endogenous platelet-activating factor and effect of saline infusion.
August 1991, Critical care medicine,
F Masugi, and T Ogihara, and S Saeki, and K Sakaguchi, and Y Kumahara, and K Satouchi, and M Oda, and K Saito, and K Tokunaga
Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity.
December 2004, Journal of medicinal chemistry,
F Masugi, and T Ogihara, and S Saeki, and K Sakaguchi, and Y Kumahara, and K Satouchi, and M Oda, and K Saito, and K Tokunaga
[Determination of platelet activating factor and platelet associated IgG in pregnancy-induced hypertension].
May 1996, Zhonghua fu chan ke za zhi,
Copied contents to your clipboard!